The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1331
February 8, 2010
View Complete Issue         Table of Contents 2019 
Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
February 8, 2010 (Issue: 1331)
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
Article code: 1331c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.